Wednesday, September 3, 2025<\/p>\n
NIH-funded clinical trial shows potential to simplify treatment for early syphilis.<\/p>\n
\u00a0<\/strong>Researchers funded by the National Institutes of Health (NIH) have found that a single injection of the antibiotic benzathine penicillin G (BPG) successfully treated early syphilis just as well as the three-injection regimen used by many clinicians in the United States and elsewhere. These findings from a late-stage clinical trial suggest the second and third doses of conventional BPG therapy do not provide a health benefit. The results were published today in The New England Journal of Medicine.<\/p>\n \u201cBenzathine penicillin G is highly effective against syphilis, but the three-dose regimen can be burdensome and deter people from attending follow-up visits with their healthcare providers,\u201d said Carolyn Deal, Ph.D., chief of the enteric and sexually transmitted infections branch of NIH\u2019s National Institute of Allergy and Infectious Diseases (NIAID). \u201cThe new findings offer welcome evidence for potentially simplifying treatment with an equally effective one-dose regimen, particularly while syphilis rates remain alarmingly high.\u201d<\/p>\n Syphilis is a common sexually transmitted infection (STI) caused by the bacterium Treponema pallidum. The United States reported 209,253 total syphilis cases and 3,882 congenital syphilis<\/a> cases in 2023, representing 61% and 108% increases over 2019 numbers, respectively. Without treatment, syphilis can result in neurological and organ damage as well as severe pregnancy complications and congenital abnormalities. Syphilis can also increase a person\u2019s likelihood of acquiring or transmitting HIV.<\/p>\n BPG is one of the few antibiotics known to effectively treat syphilis, and stockouts are common worldwide. The antibiotic is currently being imported to the United States to resolve a nationwide shortage<\/a>.<\/p>\n The study was conducted at ten U.S. sites and enrolled 249 participants with early syphilis, which encompasses the primary, secondary, and early latent<\/a> stages of disease. Sixty-four percent of participants were living with HIV and 97% were men. The participants were randomly assigned to receive either a single intramuscular (IM) injection of BPG 2.4 million units (MU) or a series of three IM injections of BPG 2.4 MU at weekly intervals. All participants were monitored for safety. Biological markers of successful treatment in the blood\u2014known as the serologic response to therapy\u2014were examined at six months following treatment.<\/p>\n Seventy-six percent of participants in the single-dose group had a serologic response to treatment compared to 70% of participants in the three-dose group. The difference between groups was not statistically significant, even when participants were stratified by HIV status. One participant developed signs of neurosyphilis three days after starting BPG therapy and was excluded from the analysis. Three serious adverse events were reported but were not related to BPG.<\/p>\n \u201cSyphilis has been studied and treated for more than a century, and BPG has been in use for more than 50 years, yet we are still acquiring knowledge to help us optimize treatment,\u201d said Principal Investigator Edward W. Hook III, M.D., emeritus professor of medicine and epidemiology at the University of Alabama at Birmingham. \u201cWe hope these promising results will be complemented by scientific advances in syphilis prevention and diagnosis.\u201d<\/p>\n According to the study authors, the results from this trial provide substantial evidence that single-dose BPG 2.4 MU is as effective as three doses in treating early syphilis. More research is needed to understand the full potential of this abbreviated treatment strategy and to evaluate therapeutic approaches for all stages of syphilis, including late syphilis, latent syphilis of unknown duration, and clinical neurosyphilis.<\/p>\n The study was conducted through the NIAID-funded Sexually Transmitted Infections Clinical Trials Group.<\/p>\n For more information about this trial, please visit ClinicalTrials.gov using the study identifier \u00a0NCT03637660<\/a>.<\/p>\n NIAID conducts and supports research\u2014at NIH, throughout the United States, and worldwide\u2014to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID website<\/a>.<\/p>\n About the National Institutes of Health (NIH):<\/strong> NIH, the nation’s medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov<\/a>.<\/p>\n NIH\u2026Turning Discovery Into Health\u00ae<\/p>\n","protected":false},"excerpt":{"rendered":"Wednesday, September 3, 2025 NIH-funded clinical trial shows potential to simplify treatment for early syphilis. \u00a0Researchers funded by…\n","protected":false},"author":2,"featured_media":41833,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[78],"tags":[6185,31648,17928,18,135,19,17,31647,31646,172,31650,31649],"class_list":{"0":"post-41832","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-health","8":"tag-antibiotic","9":"tag-dose","10":"tag-early","11":"tag-eire","12":"tag-health","13":"tag-ie","14":"tag-ireland","15":"tag-niaid","16":"tag-nih","17":"tag-research","18":"tag-syphilis","19":"tag-treats"},"share_on_mastodon":{"url":"","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/41832","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/comments?post=41832"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/41832\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media\/41833"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media?parent=41832"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/categories?post=41832"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/tags?post=41832"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}